Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

Literature DB >> 11897608

Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

Ellie J C Goldstein¹, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen Fernandez.

Abstract

We studied the in vitro activity of ertapenem against 469 less frequently identified anaerobes from 11 genera and 52 species isolated from human infections. Ertapenem was uniformly active against 460 of 469 (98%) strains at concentrations of < or = 4 microg/ml. Only 4 of 14 Clostridium difficile, 1 of 11 Clostridium innocuum, and 4 of 6 Lactobacillus sp. strains required ertapenem concentrations of > or = 8 microg/ml for inhibition.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 11897608 PMCID： PMC127089 DOI： 10.1128/AAC.46.4.1136-1140.2002

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

Authors: P C Fuchs; A L Barry; S D Brown
Journal: J Antimicrob Chemother Date: 1999-05 Impact factor: 5.790

2. Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors: E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191

3. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors: J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal: Antimicrob Agents Chemother Date: 1999-05 Impact factor: 5.191

4. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors: J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

5. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.

Authors: G Jacoby; P Han; J Tran
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

6. National hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement.

Authors: E J Goldstein; D M Citron; R J Goldman
Journal: J Clin Microbiol Date: 1992-06 Impact factor: 5.948

5. Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption.

Authors: Jakapat Vanichanan; Violeta Chávez; Audrey Wanger; Aleksandra M De Golovine; Karen J Vigil
Journal: Infection Date: 2016-05-03 Impact factor: 3.553

5 in total

Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

1. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

2. Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

3. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

4. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

5. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.

6. National hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement.

7. United States National Hospital Survey of anaerobic culture and susceptibility methods, II.

8. Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis.

9. Lactate dehydrogenase activity as a cause of metronidazole resistance in Bacteroides fragilis NCTC 11295.

10. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

Review 1. Ertapenem: a review of its use in the treatment of bacterial infections.

2. In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

Review 3. Comparative review of the carbapenems.

Review 4. Ertapenem: a review of its use in the management of bacterial infections.

5. Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption.